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Approximately 5-10% of asthmatics are barely controlled or
clinically and/or functionally uncontrolled despite a high
dose of inhaled corticosteroids (ICS) plus another controller
agent (e.g., long-acting beta2-agonists, LABA; leukotriene-
receptor antagonists, LTRA; long-acting muscarinic agents,
LAMA) or maintenance oral corticosteroid therapy. These
patients are defined as affected by “severe asthma” according
to the most recent recommendations of the European Respi-
ratory Society (ERS) and the American Thoracic Society [1].
The diagnosis of severe asthma is made after having ruled
out or having treated clinical conditions that may mimic
asthmatic symptoms (e.g., extra-thoracic hyperresponsive-
ness syndromes, vocal cord dysfunction), comorbidities that
may worsen disease control (e.g., allergic or nonallergic
rhinitis, chronic rhinosinusitis with or without nasal polyps,
bronchiectasis, and gastroesophageal reflux), possible incor-
rect inhaler techniques, and/or poor treatment adherence.
During the past decade, advanced research brought insight
into the heterogeneous mechanisms of severe asthma and
helped to reveal several potential therapeutic targets [2].
Following the introduction of the first available biologic
agents in clinical practice, the way of diagnosing and manag-
ing the majority of patients with severe asthma dramatically
changed from a “one-size-fits-all” approach to precision
medicine [3]. Presently, we are experiencing a new era in
the management of severe asthmatic patients, as subjects are
clinically characterized in phenotypes [4] or in treatable traits
[5] in order to personalize their disease-management.
In this special issue, the latest knowledge and novel
findings in severe asthma pathogenesis, pheno/endotyping
andmanagement with a particular focus on personalized and
precision medicine approaches, have been addressed.
The classification of patients according to their phe-
notypes and/or endotypes [4] is strictly dependent on the
identification of reliable biomarkers, ideally noninvasive and
available for point-of-care [6]. The article by E. Mortaz et al.
elegantly summarizes a plethora of possible new biomark-
ers from tissue-derived exosomes. These small membrane-
enclosed vesicles contain mRNA and miRNA, lipids, and a
vast array of different proteins depending on their cell of
origin. Furthermore, exosomes may also be potentially used
for developing novel therapeutic strategies. C. Galeone et al.
pointed their attention on how the new field of “omics” sci-
ences (including proteomics, metabolomics, transcriptomics,
and genomics)may provide new biomarkers, novel targets for
diagnostic tests, and pharmacological treatments.
This complex scenario of new technologies and biomark-
ers, applied to the process of identification of specific severe
asthma phenotypes and endotypes, is part of the precision
medicine approach to asthma. The direct consequence of a
better characterization of patients under the immunological
point of view is the possibility to treat them with novel
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biologic agents, acting directly towards those immunological
mechanisms that are involved in every single endotype of
severe asthma [7]. The first available biologic agent for
severe asthma was omalizumab, a fully humanized anti-IgE
monoclonal antibody. Its clinical efficacy and effectiveness
in severe allergic patients have been proved extensively.
There are some recent studies also suggesting effectiveness in
nonallergic severe asthmatics. C. C. Loureiro et al. reviewed
the current evidence on both of these possible uses of
omalizumab in this present Special Issue. In the past few
years, novel therapeutic targets have been addressed by
recently approved biologic agents: mainly, anti-IL5 strategies
are currently worldwide used for severe eosinophilic asthma
[8]. D. Bagnasco et al. overviewed the possible molecular
targets and related biologic drugs, blocking the IL5-mediated
eosinophilic inflammation in severe asthma. C. Pelaia et al.
dedicated their review article to the specific mechanism and
clinical effects of benralizumab, an afucosylated monoclonal
antibody towards the IL5-receptor, a newly approved drug
for treatment of severe asthma in 2018. This drug has a
remarkable affinity for the Fc𝛾RIIIa receptor of NK cells that
gives to the drug the ability to induce the apoptotic mecha-
nism named antibody-dependent cell-mediated cytotoxicity
(ADCC). L. Brussino et al. critically revised the published
literature on anti-IL5 treatment in asthma and highlighted the
still present unmet needs, critical points, and open questions
on efficacy and real-life effectiveness of this category of drugs
in severe asthmatics.
Beyond the use of biologic agents, among the approved
drugs for severe asthma, the inhaled LAMA tiotropium may
play a role, both before starting any biologic treatment and
for those patients not meeting the indication for any of the
currently available biologics. E. Hamelmann et al. reviewed
the evidence of the use of inhaled tiotropium in severe
asthmatics.
A critical point for all treatments for severe asthma is
the a priori identification of responder patients: this depends
on many variables (e.g., clinical, functional and immuno-
logical characteristics, associated comorbidities) that may
not correspond precisely to the features of the extremely
selected patients included into randomized-controlled trials.
Therefore, real-life big-data on severe asthma are needed
to improve the characterization of our patients and provide
them with adequate and tailored treatment. A very effective
approach to obtain real-life big-data is establishing national
and international registries [9, 10], as they will include a
large amount of information on “real” patients managed by
physicians in their daily clinical activity. A. Sa´-Sousa et al., in
this special issue, described the protocol and the aims of such
an initiative, the Portuguese Severe Asthma Registry.
In conclusion, this special issue updates and summarizes
recent knowledge onmany different aspects of severe asthma.
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